MD Anderson’s Christopher Flowers Recognized for Excellence in Teaching and Mentorship at ASCO

CHICAGO, MAY 27, 2025 — Dr. Christopher Flowers, a world-renowned expert in lymphoma clinical research and the division head of Cancer Medicine at The University of Texas MD Anderson Cancer Center, has been awarded the prestigious Jamie Von Roenn Excellence in Teaching and Mentorship Award. This distinguished honor will be presented to Dr. Flowers at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, recognizing his unwavering dedication to mentoring the next generation of oncology professionals and his profound impact on cancer medicine.

Dr. Flowers’s career is marked by groundbreaking achievements in the field of lymphoma research and population science. His work has been pivotal in advancing multiple novel therapeutic approaches and elucidating the disparities in lymphoma patient outcomes. These contributions have significantly shaped modern treatment paradigms, offering hope for personalized medicine tailored to molecular and genetic tumor profiles. More than a clinician-scientist, Dr. Flowers is lauded for his deep commitment to fostering talent and leadership within the oncology community.

The Jamie Von Roenn Award stands as one of ASCO’s highest honors, celebrating individuals whose mentorship and teaching have fundamentally transformed cancer research and patient care globally. Dr. Flowers’s impact resonates not only through his own scientific output but also through the successful careers of his mentees. Under his guidance, a remarkable number of young oncologists have emerged as influential faculty members at premier academic institutions across the United States.

Throughout his distinguished career, Dr. Flowers has played an instrumental role in professional organizations, including ASCO, the American Society of Hematology (ASH), and the American Association for Cancer Research (AACR). His involvement extends beyond research to strategic mentorship initiatives designed to enhance workforce diversity and inclusion in oncology careers. These programs are critical to sustaining innovation and addressing emerging challenges in cancer treatment.

Leadership in mentorship is a recurring theme in Dr. Flowers’s professional journey. He has helmed a National Cancer Institute K24 grant focused on mentored patient-oriented research, demonstrating his commitment to career development in lymphoma research. Additionally, his co-chairmanship of the Lymphoma Research Foundation’s Scientific Research Mentorship Program and active participation in the ASH Clinical Research Training Institute exemplify his dedication to nurturing aspiring cancer investigators.

Dr. Flowers’s mentorship philosophy is characterized by creating structured opportunities for young researchers while promoting rigorous scientific inquiry. His mentees have thrived, with many securing competitive ASCO Young Investigator Awards, underscoring the effectiveness of his guidance. Notably, MD Anderson’s Division of Cancer Medicine, under his leadership, boasts a substantial cohort of awardees, reflecting the division’s recognition as a leading incubator of early-career oncology talent.

Scientifically, Dr. Flowers’s work in lymphoma encompasses comprehensive epidemiological studies that have redefined the understanding of lymphoma subtypes and their clinical outcomes. His seminal involvement in the first broad assessment of World Health Organization (WHO) lymphoma classifications has had far-reaching implications for disease stratification and clinical trial design. These epidemiologic insights inform precision medicine approaches that stratify risk and optimize therapeutic regimens.

Dr. Flowers’s extensive publication record—exceeding 300 peer-reviewed articles—demonstrates his profound influence on oncology literature. His research often bridges clinical observation with molecular biology, providing a translational perspective that accelerates bench-to-bedside advances. Through federally funded research, including multiple U01 awards and multi-institutional collaborations, he continues to drive innovation in lymphoma treatment strategies and survivorship care.

The impact of Dr. Flowers’s mentorship has been repeatedly acknowledged through various awards, consolidating his reputation as a pillar of oncology education. Previously honored by Emory School of Medicine, Lymphoma Research Foundation, and ASH, he recently received the 2025 AACR Jane Cooke Wright Award, further affirming his leadership role in fostering the careers of future cancer investigators. These accolades highlight a continuous trajectory of excellence in teaching and mentorship.

Institutional leaders at MD Anderson emphasize the invaluable role Dr. Flowers plays in advancing the institution’s mission. Peter WT Pisters, M.D., MD Anderson’s president, commends Dr. Flowers’s extraordinary commitment to mentoring, which not only cultivates talent but also propels the broader goal of ending cancer through scientific discovery and clinical excellence. Giulio Draetta, M.D., Ph.D., the institution’s chief scientific officer, echoes this sentiment, recognizing Dr. Flowers’s scientific and mentorship contributions as pivotal for transformative cancer research.

Dr. Flowers’s dual role as a pioneering researcher and mentor exemplifies the evolving paradigm of academic medicine, where scientific innovation and dedicated training are inextricably linked. His emphasis on personalized therapeutics anchored in genomic and molecular tumor profiling has reshaped lymphoma management, improving patient outcomes and quality of life. Simultaneously, his mentorship ensures that these advances are carried forward by a new cadre of investigators prepared to tackle future challenges in oncology.

As the cancer research community gathers at the upcoming ASCO Annual Meeting, Dr. Flowers’s recognition sends a powerful message about the central importance of mentorship in scientific progress. Cultivating the next generation of oncology leaders is essential not only for sustaining research momentum but also for translating complex biological insights into tangible patient benefits. Dr. Flowers’s career provides a blueprint for integrating research excellence with educational leadership in the fight against cancer.

For more information about MD Anderson’s participation in the 2025 ASCO Annual Meeting and ongoing contributions to clinical oncology, visit MDAnderson.org/ASCO.

News Publication Date: May 27, 2025

Web References:

• https://faculty.mdanderson.org/profiles/christopher_flowers.html
• https://connection.asco.org/do/asco-congratulates-2025-special-awards-recipients
• https://www.mdanderson.org/research/research-resources/conferences-seminars/md-anderson-at-asco.html